Bone Marrow and Stem Cell Treatment

Overview

Bone marrow and stem cell treatment replaces diseased or damaged bone marrow with healthy blood-forming (haematopoietic) stem cells, allowing the body to rebuild healthy blood and immune cells. It is often called a stem cell transplant or bone marrow transplant, and it is a cornerstone of treatment for a number of blood cancers and some other serious conditions.

The stem cells may come from the patient (an autologous transplant) or from a matched donor (an allogeneic transplant). A high dose of chemotherapy, sometimes with radiotherapy, is usually given first to clear the diseased marrow, after which the stem cells are returned by drip to regrow a healthy blood system.

This page is an educational overview only and is not medical advice. Whether a transplant is appropriate, and which type, can only be decided by a specialist haematology and transplant team, and no outcome can be guaranteed.

Who May Need This

Transplantation may be considered for people with blood cancers such as leukaemia, lymphoma and myeloma, and for some non-cancer conditions including severe aplastic anaemia, certain inherited immune deficiencies and metabolic disorders, and, in selected cases, thalassaemia and sickle cell disease. It is used when the potential benefit outweighs the significant risks.

Suitability depends on the specific diagnosis and its response to earlier treatment, the patient's age and overall fitness, organ function, and, for allogeneic transplants, the availability of a well-matched donor. A transplant specialist assesses all of these before recommending the approach.

When It May Be Recommended

An autologous transplant is often recommended to consolidate and prolong remission in conditions such as myeloma and some lymphomas after initial treatment. An allogeneic transplant may be recommended for higher-risk leukaemias, for relapsed disease, or for marrow failure, where a new immune system from a donor can also help control the disease.

Timing is important: transplants are usually planned when the disease is in remission or best controlled and the patient is well enough. The decision weighs the chance of long-term benefit against real risks, and is made by the transplant team, often after discussion in a specialist meeting.

Diagnosis and Evaluation

Before a transplant, the underlying disease is fully assessed and its response measured, and a detailed fitness and organ assessment is carried out — heart, lungs, kidneys and liver — to check the body can tolerate intensive treatment. Blood tests, imaging and often a bone marrow biopsy are part of this work-up.

For an allogeneic transplant, tissue typing (HLA matching) identifies a suitable donor from within the family or an unrelated donor registry, or considers cord blood. Infection screening and dental and psychological assessment are also completed. This thorough evaluation ensures the plan is as safe as possible.

Treatment Options

The main options are autologous transplant (using the patient's own stored stem cells) and allogeneic transplant (using donor cells). Allogeneic transplants can use full-intensity or reduced-intensity conditioning, the latter allowing older or less fit patients to be treated with lower doses of chemotherapy.

Donor sources include matched siblings, matched unrelated donors, partially matched (haploidentical) family donors, and banked umbilical cord blood. The choice among these options depends on the disease, urgency, patient fitness and donor availability, and is individualised by the transplant team.

How It Is Performed

Stem cells are most often collected from the bloodstream by apheresis after several days of injections that mobilise them from the marrow; less commonly they are harvested directly from the hip bone under anaesthesia, or cord blood is used. The patient then receives conditioning treatment — high-dose chemotherapy, sometimes with radiotherapy — to clear the diseased marrow.

The stem cells are then given back through a drip, much like a blood transfusion, and travel to the bone marrow where they begin to grow (engraftment). Over the following weeks, blood counts gradually recover while the patient is protected from infection and supported with transfusions and medicines.

Preparation

Preparation includes completing the fitness assessment, treating any infection, ensuring good dental health, and arranging a reliable central line for delivering treatment and taking blood. For allogeneic transplants, donor arrangements and matching are finalised. Vaccinations, nutrition and psychological support are part of getting ready.

If you are travelling for treatment, bring complete records of your diagnosis, prior treatment and organ function tests. A transplant requires a lengthy stay and close local follow-up afterwards, so plan the in-country period carefully and arrange continuing care at home before you travel.

Benefits and Expected Goals

The goal is to give the best available chance of long-term disease control or, for some conditions, cure, by rebuilding a healthy blood and immune system. Allogeneic transplants can add a graft-versus-tumour effect, in which donor immune cells help destroy remaining cancer cells.

Benefits depend heavily on the underlying condition, its stage and response, and the transplant type, and cannot be guaranteed. Because transplantation carries serious risks, the team carefully weighs the likely benefit for each individual and explains realistic goals before proceeding.

Risks and Possible Complications

Transplantation is intensive treatment with significant risks that require expert management.

• Serious infections during the period of low blood counts
• Bleeding and the need for blood and platelet transfusions
• Graft-versus-host disease after allogeneic transplant, affecting the skin, gut and liver
• Damage to organs such as the lungs, liver or kidneys from conditioning treatment
• Graft failure, relapse of the original disease, infertility, and late effects requiring long-term follow-up

Specialist centres monitor closely and use preventive and treatment measures for these complications. The team will explain the specific risks for your transplant type and disease.

Recovery, Follow-up & Aftercare

Early recovery, while blood counts rebuild, usually takes a few weeks in or close to hospital with strict infection precautions. Regaining full strength and immunity — especially after an allogeneic transplant — can take many months to a year or more, with ongoing medicines to prevent infection and, if needed, to manage graft-versus-host disease.

Follow-up includes frequent blood tests, monitoring for infection and complications, re-vaccination in due course, and checks for disease relapse and late effects. Continuity of care is essential, so if you were treated abroad, arrange detailed handover and long-term follow-up with your home team.

Medical Tourism Planning

Transplantation demands specialist facilities and lengthy follow-up, so choose a JCI- or ISO-accredited hospital with an accredited transplant programme, protected isolation facilities, and strong intensive care and infection services. Confirm donor arrangements, the transplant type, and the full plan in writing.

Plan for an extended in-country stay covering the transplant and early recovery, and ensure your home team can provide the prolonged monitoring that follows. Clarify how complications would be handled, arrange clear medical handover, and consider comprehensive medical travel insurance.

Estimated Cost Factors

Cost depends on the transplant type (autologous transplants are generally less complex than allogeneic), donor search and matching where relevant, the length of hospital and isolation stay, conditioning treatment, and management of complications such as infection or graft-versus-host disease.

Many destinations offer transplantation at a fraction of typical US prices, but costs vary widely by type and by any complications, and cannot be judged from online figures. Always request a personalized written quote covering the whole pathway and what is included before deciding.

Choosing a Hospital or Specialist

Look for a hospital with recognised accreditation, a dedicated and, ideally, transplant-accredited haematology programme, experienced transplant physicians, and robust supportive and intensive care. Ask about the centre's transplant volumes and outcomes and how they manage complications.

Ask about international patient services, interpreter support, donor arrangements, and how the essential long-term follow-up would be shared with your home doctors. Written treatment and cost plans are marks of a quality programme.

Alternatives

Depending on the disease, alternatives to transplantation include continued drug therapy (chemotherapy, targeted or immunotherapy), maintenance treatment, or, for some conditions, newer cellular therapies such as CAR T-cell treatment. For less aggressive disease, ongoing monitoring may be appropriate.

Because transplantation carries substantial risks, the decision always compares it against these alternatives for the individual. Clinical trials may offer additional options. Discuss all approaches with your haematology team so the plan fits your condition and priorities.

Questions to Ask Your Doctor

• Do I need an autologous or allogeneic transplant, and why?
• Is a suitable donor available, and how well matched?
• What conditioning treatment will I have, and what are its effects?
• What are the specific risks, including graft-versus-host disease and infection?
• What are the realistic goals of the transplant for my condition?
• How long will I need to stay near the hospital, and what follow-up is required?
• If I travel, how will long-term care be shared with my home team?
• What is included in the written cost estimate?